Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072449 · OUTCOME

Toxicity

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma · Source last updated 2013-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
related episodes
Interval / dispersion
Not reported
Time frame
8 weeks - 2 cycles

What was measured

patients only received drug for 8 weeks

Groups in this outcome

Rituximab Monotherapy

Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rituximab Monotherapy12

Reported measurements

Source class 1
Values in related episodes · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rituximab Monotherapy4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
patients only received drug for 8 weeks
groups
  1. description
    Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
    id
    OG000
    title
    Rituximab Monotherapy
param Type
NUMBER
reporting Status
POSTED
time Frame
8 weeks - 2 cycles
title
Toxicity
type
SECONDARY
unit Of Measure
related episodes

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice